Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 3,305 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diseases of the Circulatory System Clear all
Terminated Phase 1Phase 2 Interventional

Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT03492138
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ONC201, Ixazomib, Dexamethasone
Drug
Lead sponsor
Ajai Chari
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Oct 17, 2026, 12:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Caffeine on Heart Function

NCT02401776
View directory record Official record
Conditions
Fatigue, Tachycardia
Interventions
Monster Energy Drink, Coffee
Dietary Supplement
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 35 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 17, 2026, 12:10 PM EDT
Terminated Phase 4 Interventional Results available

Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure

NCT04071626
View directory record Official record
Conditions
Heart Failure, Diastolic, Diabetes Mellitus, Type 2
Interventions
Ertugliflozin 5 mg, Placebo oral tablet
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 17, 2026, 12:10 PM EDT
Recruiting Phase 2 Interventional

The CARDIOPROTECT Trial

NCT07654426
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Interventions
Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 17, 2026, 12:10 PM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke

NCT00073476
View directory record Official record
Conditions
Stroke
Interventions
traxiprodil (CP-101,606)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
12
States / cities
La Mesa, California • Atlanta, Georgia • Fort Wayne, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2006 · Synced Oct 17, 2026, 12:10 PM EDT
Completed Not applicable Interventional Results available

Safety and Performance Study of the INGEVITY Lead

NCT01688843
View directory record Official record
Conditions
Bradycardia, Sinus Node Dysfunction
Interventions
INGEVITY lead
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
44
States / cities
Gilbert, Arizona • Glendale, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 17, 2026, 12:10 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06121843
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BMS-986393, Alnuctamab, Mezigdomide, Iberdomide, Elranatamab, Dexamethasone
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 17, 2026, 12:10 PM EDT
Completed Phase 1 Interventional

Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

NCT00594126
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Imetelstat Sodium (GRN163L)
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 17, 2026, 12:10 PM EDT
Completed Phase 1 Interventional

MS-275 in Treating Patients With Hematologic Cancer

NCT00015925
View directory record Official record
Conditions
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
entinostat
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2010 · Synced Oct 17, 2026, 12:10 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function

NCT00652626
View directory record Official record
Conditions
MDS, AML, Solid Tumors, Multiple Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's Disease
Interventions
azacitidine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
11
States / cities
Berkeley, California • Hialeah, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 17, 2026, 12:10 PM EDT
Recruiting Not applicable Interventional

Acute Pulmonary Embolism Treatment With the AlphaVac Multipurpose Mechanical Aspiration System and the AlphaReturn Blood Management System: Evaluation of Safety and Effectiveness

NCT07280247
View directory record Official record
Conditions
Pulmonary Embolism Acute
Interventions
AlphaReturn Blood Management System
Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
6
States / cities
Saint Cloud, Minnesota • Buffalo, New York • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 17, 2026, 12:10 PM EDT
Completed Not applicable Interventional Results available

PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease

NCT03168776
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
BuMA Supreme DES, Xience or Promus DES
Device
Lead sponsor
Sino Medical Sciences Technology Inc.
Industry
Eligibility
20 Years and older
Enrollment
1,629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
40
States / cities
Birmingham, Alabama • Gilbert, Arizona • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 17, 2026, 12:10 PM EDT
Terminated Phase 1 Interventional

Cold Heart Study: A Randomized Pilot Trial of Surfactant Therapy

NCT04181255
View directory record Official record
Conditions
Congenital Heart Disease, Hypoplastic Left Heart Syndrome
Interventions
Curosurf, Sham
Drug
Lead sponsor
University of Michigan
Other
Eligibility
1 Day to 12 Weeks
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 17, 2026, 12:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Trial of Pharmacist Management of Oral Anticoagulation THerapy in the communitY for AF

NCT04907825
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
Oral anticoagulant
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
60 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 17, 2026, 12:10 PM EDT
Recruiting Not applicable Interventional

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

NCT05646576
View directory record Official record
Conditions
Hematologic Malignancy, Blood Cancer, Lymphoma, Leukemia, Multiple Myeloma
Interventions
Palliative Care, Usual Care
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 17, 2026, 12:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage

NCT00009620
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Intracranial Hemorrhages
Interventions
Phenobarbital, Saline
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Female only
Enrollment
610 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 1997
U.S. locations
11
States / cities
Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 17, 2026, 12:10 PM EDT
Completed Phase 1 Interventional

Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers

NCT02652754
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Granexin® gel
Drug
Lead sponsor
Xequel Bio, Inc.
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Augusta, Georgia • Spartanburg, South Carolina • Salem, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 17, 2026, 12:10 PM EDT
Recruiting No phase listed Observational

Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients

NCT06999122
View directory record Official record
Conditions
Stroke, Hemorrhagic Stroke
Interventions
Brain Scan
Diagnostic Test
Lead sponsor
EMVision Medical Devices Ltd
Network
Eligibility
22 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Jacksonville, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 17, 2026, 12:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Effects of Estrogen on Cognition in Girls With Turner Syndrome

NCT00001253
View directory record Official record
Conditions
Gonadal Dysgenesis, Turner's Syndrome
Interventions
cognitive tests and scales
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
950 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1990 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 12:10 PM EDT
Completed Not applicable Interventional Results available

Using Non-Fluoroscopic Imaging Devices to Decrease Radiation Exposure During Ablation of Supraventricular Tachycardia

NCT00979303
View directory record Official record
Conditions
Supraventricular Tachycardia
Interventions
Intracardiac echocardiography and 3D navigational system
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 21 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Oct 17, 2026, 12:10 PM EDT
Terminated No phase listed Observational

Wound Imaging Study to Gather Clinical References for a Device to Assist Selecting Level-of-amputation in PAD Patients

NCT03611361
View directory record Official record
Conditions
Amputation Wound, Peripheral Arterial Disease
Interventions
SpectralMD DeepView Wound Imaging System 2.0
Device
Lead sponsor
SpectralMD
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Timeline
2015 – 2020
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 17, 2026, 12:10 PM EDT
Completed Not applicable Interventional

Role of Aging and Individual Variation in Exercise Training Responsiveness

NCT06471569
View directory record Official record
Conditions
Prediabetic State, Cardiovascular Diseases, Insulin Resistance, Obesity
Interventions
Low/Mod, High/Mod, High/Vig
Behavioral
Lead sponsor
Duke University
Other
Eligibility
60 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 17, 2026, 12:10 PM EDT
Completed Early Phase 1 Interventional

Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)

NCT02851056
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Survivin Vaccine, Autologous Hematopoietic Cell Transplantation, Prevnar 13, Granulocyte-colony Stimulating Factor
Biological · Procedure · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 17, 2026, 12:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications

NCT03973931
View directory record Official record
Conditions
Cardiovascular Diseases, Adherence, Medication, Medication Adherence, Diabetes Mellitus, Hypertension, Hyperlipidemias, Coronary Artery Disease, Atrial Fibrillation
Interventions
Nudge
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
9,501 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
4
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 17, 2026, 12:10 PM EDT